Rhythm Pharmaceuticals Inc
Cerrado
SectorSanidad
104.62 2.4
Resumen
Variación precio
24h
Mínimo
103.67
Máximo
106.1
Ingresos | -49M -105M |
|---|---|
Ventas | 11M 71M |
BPA | -0.73 |
Margen de beneficios | -147.27 |
Empleados | 414 |
EBITDA | 6.2M -44M |
Próximas Ganancias | 3 nov 2026 |
|---|
Capitalización Mercado | 24M 7.1B |
|---|---|
Apertura anterior | 102.22 |
Cierre anterior | 104.62 |
Noticias sobre sentimiento de mercado
By Acuity
64%
36%
285 / 339 Clasificación en Healthcare
Rhythm Pharmaceuticals Inc Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Rhythm Pharmaceuticals Inc previsión
Sentimiento
By Acuity
285 / 339 Clasificación en Sanidad
Noticias sobre sentimiento de mercado
Coyuntura bajista
Volatilidad
Por debajo de la media
Volumen de Noticias (RCV)
Por debajo de la media
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.